Cytoplasmic polyadenylation element binding protein 4 (CPEB4) is a regulator of gene transcription and has been reported to be associated with biological malignancy in cancers. However, it is unclear whether CPEB4 has any clinical significance in patients with astrocytic tumors, and mechanisms that CPEB4 contribute to progression of astrocytic tumors remain largely unknown. Here, correlation between CPEB4 expression and prognosis of patients with astrocytic tumors were explored by using qPCR, WB and IHC, and X-tile, SPSS software. Cell lines U251 MG and A172 were used to study CPEB4's function and mechanisms. Co-immunoprecipitation, mass spectrometry, immunofluorescent assay, and western blot were performed to observe the interaction between CPEB4 and Vimentin. CPEB4 mRNA and protein levels were markedly elevated in 12/12 astrocytic tumors in comparison to paratumor. High expression of CPEB4 was significantly correlated with clinical progressive futures and work as an independent adverse prognostic factor for overall survival of patients with astrocytic tumors (relative risk 4.5, 95 % CI 2.1-11.2, p = 0.001). Moreover, knockdown of CPEB4 in astrocytic tumor cells inhibited their proliferation ability , clonogenicity, and invasiveness. Five candidate proteins, GRP78, Mortalin, Keratin, Vimentin, and β-actin, were identified, and the interaction between CPEB4 and Vimentin was finally confirmed. Downregulation of CPEB4 could reduce the protein expression of Vimentin. Our studies first validated that CPEB4 interacts with Vimentin and indicated that high CPEB4 expression in astrocytic tumors correlates closely with a clinically aggressive future, and that CPEB4 might represent a valuable prognostic marker for patients with astrocytic tumors.

Background and purpose: As the postoperative recurrence of meningioma can have devastating effects, it is important to identify factors that can be used to predict this type of tumor recurrence. Material and methods: We have performed a retrospective study involving 138 patients who were surgically treated for intracranial meningioma between 2005 and 2010. The patient population consisted of 80 females and 58 males, with an age range of 23 to 77 years old (mean age = 52 years). We measured associations between meningioma recurrence and clinical features (age, sex, extent of resection, histological type), or radiological features (tumor size, location, shape, calcification, bone changes, brain tumor interface, tumor necrosis, and MRI enhancement). Results: We found statistically higher levels of postoperative meningioma recurrence in patients with high Simpson grade resections, high histological types, tumor diameters > 5 cm, tumors located in the base of the skull or the parasagittal sinus, tumors with unclear border, irregular enhancements on MRI, edema around the tumor, bleeding and necrosis within the tumor, and irregularly shaped tumors (e.g., lobulated or mushroom-shaped). In addition, calcification, age, sex, bone change, and dural tail sign provided no predictive value. C onclusions: We have shown that histological type, degree of resection, bleeding, necrosis, edema, irregular enhancement, location, shape, size, and margin serve as strong predictors for the postoperative recurrence of meningioma tumors.

Objective: The mortality of re-bleeding is high and patients surviving are usually in poor clinical condition and have a worse outcome than patients with single bleed. We performed an update systemic review and Meta-analysis to determine the most common risk factors for re-bleeding in aneurysmal subarachnoid hemorrhage patients.

Neurosurgical intervention through a temporal approach with linear incision is warranted in patients with radiation induced temporal lobe necrosis with significant symptoms and signs of increased intracranial pressure, minimum space occupying effect on imaging, or neurological deterioration despite conservative management.